Table 2.
Prevalence of DPYD Mutations, and Genotypic Profiles of Patients With ≥Grade 3 Toxicity.
| Gene mutation | Prevalence of the mutation in the patient population Number & (%) N = 472 patients |
Patients with Grade 3 toxicity Number & (%) † N = 97 patients |
Patients with Grade 4 toxicity Number & (%) † N = 128 patients |
Patients with Grade 5 toxicity Number & (%)† N = 41 patients |
|---|---|---|---|---|
|
DPYD*2A
Heterozygous (h) Homozygous (H) |
37 (7.84%) 3 (0.63%) |
10 (27.0%) 0 |
19 (51.4%) 1 (33.0%) |
6 (16.2%) 2 (66.0%) |
| hDPYD*9B | 42 (8.89%) | 8 (19%) | 22 (52.4%) | 8 (19.0%) |
| hDPYD*7 | 3 (0.63%) | 0 | 2 (66.0%) | 1 (33.0%) |
| hDPYD*13 | 3 (0.63%) | 1 (33.33%) | 2 (66.0%) | 0 |
| hDPYD*2A+ hDPYD*9B | 1 (0.21%) | 0 | 0 | 1 (100%) |
| hDPYD*2A+ hDPYD*13 | 1 (0.21%) | 0 | 0 | 1 (100%) |
| hHapB3 | 8 (1.69%) | 1 (12.5%) | 2 (25.0%) | 1 (12.5%) |
| None of the above gene mutations | 374 (79.2%) | 77 (20.6%) | 80 (62.5%) | 21 (51.2%) |
† The percentage value is the proportion of patients with the mutation that demonstrated toxicity of the stated grade.
h = heterozygous